12/10/2015 - 11:46am

Raymond Kerins, Jr., who joined Bayer in 2013 after serving in senior executive positions at Pfizer and Merck, is a veteran communications and government relations professional. 

12/10/2015 - 11:44am

The NCPA pointed out that its recent survey of pharmacists found that from their perspective, generic price spikes have gotten worst since they last conducted a survey in 2013 and are affecting both pharmacists and patients. 

12/08/2015 - 2:44pm

Steve Anderson, president and CEO of the National Association of Chain Drug Stores, as well as the president and CEO of the Arthritis Foundation, Anna Palmer, recently published an op-ed in Morning Consult about the value of Medication Therapy Management and the need to pass pending legislation that would improve access to MTM for Medicare beneficiaries. “Providing patients with better access to counseling when it comes to the safe and proper use of their medication should be a matter of commonsense,” they wrote. (Morning Consult)

12/08/2015 - 11:30am

He joins GPhA at a time that president and CEO Chip Davis called one of “unprecedented opportunities and challenges for the generic drug industry.”

12/08/2015 - 11:14am

The bill’s passage gained its sponsor praise from CHPA for the bills sponsors and the timeline it lays out for removing synthetic microbeads from products. 

12/07/2015 - 5:05pm

Since 2005 generics have saved patients $1.68 trillion, a report released by the Generic Pharmaceutical Association showed.

12/07/2015 - 5:05pm

A new, long-term pilot program from the U.S. Centers for Medicare and Medicaid Services’ Center for Medicare and Medicaid Innovation, set to launch in 11 states in January 2017, will gauge the effectiveness of an Enhanced Medication Therapy Management model.

12/07/2015 - 2:05pm

The elevation of the Division of Dietary Supplement Programs to an 'office' would provide appropriate regulatory attention to the growing industry and increase FDA’s enforcement activities and priorities, the VMS industry argued. 

12/04/2015 - 1:40pm

In the letter NACDS sent to all U.S. Senators earlier this week, the association cited the differences in active ingredients in drugs from other countries, as well as different shapes, sizes and colors, which can cause confusion for patients and healthcare professionals.